The 24-week results from a trial, DEPICT-1, people with Type 1 diabetes taking the oral selective SGLT-2 inhibitor class of diabetes medicines show that dapagliflozin, as an adjunct to insulin, provides significant and clinically relevant benefits in terms of glycaemic control and weight reduction, together with a reduction in insulin dose, and is not associated with an increase in the occurrence of hypoglycaemia or diabetic ketoacidosis.
Read more about SGLT-2 inhibitors HERE.
News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal. We cover diabetes news, diabetes management equipment (diabetes kit) and news about food suitable for a diabetic diet. Go to the top of this page to sign up – we just need your email address. www.desang-magazine.co.uk
